MAIT Cell Activation and Functions

Mucosal associated invariant T (MAIT) cells are striking in their abundance and their strict conservation across 150 million years of mammalian evolution, implying they must fulfill critical immunological function(s). MAIT cells are defined by their expression of a semi-invariant αβ TCR which recognizes biosynthetic derivatives of riboflavin synthesis presented on MR1. Initial studies focused on their role in detecting predominantly intracellular bacterial and mycobacterial infections. However, it is now recognized that there are several modes of MAIT cell activation and these are related to activation of distinct transcriptional programmes, each associated with distinct functional roles. In this minireview, we summarize current knowledge from human and animal studies of MAIT cell activation induced (1) in an MR1-TCR dependent manner in the context of inflammatory danger signals and associated with antibacterial host defense; (2) in an MR1-TCR independent manner by the cytokines interleukin(IL)-12/-15/-18 and type I interferon, which is associated with antiviral responses; and (3) a recently-described TCR-dependent “tissue repair” programme which is associated with accelerated wound healing in the context of commensal microbiota. Because of this capability for diverse functional responses in diverse immunological contexts, these intriguing cells now appear to be multifunctional effectors central to the interface of innate and adaptive immunity.

Introduction

Mucosal-associated invariant T (MAIT) cells are innate-like T cells defined by their semi-invariant αβ T cell receptor (TCR) which recognizes small-molecule biosynthetic derivatives of riboflavin synthesis (1–3) presented on the restriction molecule major histocompatibility complex (MHC)-related protein-1 (MR1) (4). MAIT cells were described in 1999 (5) based on their TCR comprising a semi-invariant TCR-α chain—usually Vα7.2–Jα33/12/20 in humans, Vα19–Jα33 in mice—predominantly associated with the β-chains Vβ2/Vβ13 in humans and Vβ6/Vβ8 in mice (5, 7).

MAIT cells contrast with conventional T cells which have highly variable TCRs, capable of targeting a vast array of peptide epitopes produced by viruses, bacteria and malignant cells. Conventional T cells therefore have exquisite specificity for individual peptides, and individual clones may undergo massive expansion, to provide T cell memory. However, at the first encounter with a pathogen the frequency of any individual peptide-specific T cell will be very low. In contrast, the MAIT cell TCR provides an innate capacity to respond to a specific set of ligands without the need for expansion.

A key discovery was the identification of these ligands presented on MR1, which include the potent MAIT cell ligands 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil (5-OP-RU) and 5-(2-oxoethylideneamino)-6-D-ribitylaminouracil (5-OE-RU) (2, 8) produced by a wide variety of bacteria, mycobacteria and yeasts during riboflavin (vitamin B2) synthesis (3, 9–12). This pathway is absent from mammals; therefore, its immune detection allows effective host-pathogen discrimination.

Several properties of MAIT cells imply fundamental roles in mammalian immunity. First, MAIT cells have an intrinsic effector-memory phenotype, usually CD45RA⁻CD45RO⁺ CD95^HiCD62L^LoCD44^Hi (4, 13–15), with capacity for rapid secretion of several pro-inflammatory cytokines (13, 15). Second, MAIT cells are remarkably abundant in human tissues, typically comprising 1–4% of all T cells in peripheral blood (16, 17) and up to 10% of airway T cells (18, 19) and 20–40% of liver T cells (13, 20). Moreover, as each TCR recognizes the same ligand, early in an immune response, MAIT cells will markedly exceed the numbers of conventional antigen-specific T cells responding to cognate antigens. Third, the MR1-MAIT cell axis is strikingly conserved across 150 million years of mammalian evolution (21), with ~90% sequence homology for MR1 between mouse and human (21), implying a strong evolutionary pressure maintaining the MAIT cell repertoire. Nonetheless identifying the critical functional role(s) played by these cells has not proved straightforward, perhaps because these cells perform not a single, but several distinct functions. Indeed, several new MAIT cell functions have recently been discovered, representing distinct transcriptional programs which can be triggered via distinct activation pathways.

Here we review both the mechanisms and requirements for MAIT cell activation, and our current understanding of their diverse functional roles, including response to bacterial infections, viral infections and tissue repair. Consequently, these diverse roles suggest the potential to harness MAIT cells in protection against infectious disease, in vaccine design and in promoting wound healing.

MAIT Cell Activation

TCR Mediated Activation

MAIT cells can be activated in response to TCR ligation by riboflavin intermediates presented on MR1, under co-stimulatory signals from specific cytokines or toll-like receptors (TLR) (22). Activated cells expand substantially inducing a rapid innate-like immune response and effector functions including anti-microbial cytotoxic products, inflammatory chemokines, and cytokines.

During riboflavin biosynthesis, the pyrimidines 5-OP-RU and 5-OE-RU are generated from the precursor 5-amino-6-D-ribitylaminouracil (5-A-RU) by non-enzymatic condensation with methylglyoxal and glyoxal, respectively (1, 2, 23). RibD is a key gene in this pathway, encoding a pyrimidine deaminase/reductase that generates 5-A-RU. RibD expression correlates with MAIT cell response (24). Thus, bacteria possessing this pathway, for instance, Escherichia, Lactobacillus, Staphylococcus (9), Shigella Flexneri (25), Salmonella, Mycobacteria, and Clostridioides species (3, 9, 26) besides Mycobacteria (27) or fungi equipped with riboflavin synthesis, such as Saccharomyces (9), Candida (9, 28), and Aspergillus (29) can activate MAIT cells in an MR1-dependent manner, while other bacterial species lacking the full riboflavin pathway such as Enterococcus faecalis (9) and Listeria monocytogenes (27) are not.

Unlike conventional T cells which recognize peptide antigen presented by MHC molecules, MAIT cells are restricted by MR1, a non-polymorphic, β2-microglobulin-associated antigen-presenting molecule, widely expressed in multiple tissues (30, 31). Unlike class 1 and class 2 MHC, MR1 does not constitutively present self-ligands. Generally, MR1 molecules reside in the endoplasmic reticulum (ER) in an incompletely folded ligand-receptive conformation, free of β2 microglobulin. Riboflavin metabolites are transported to the ER, bind MR1 via formation of a Schiff base, followed by a complete folding and association with β2-microglobulin. The ternary complex then traffics through the ER and the Golgi to the cell membrane (32). Although recycling of the MR1 molecule can occur (33), most MR1 molecules are degraded and reinternalized intracellularly, which contributes to MR1's rapid presentation of extracellular riboflavin antigens and MAIT cells' rapid activation (32). Moreover, NF-κB signaling is necessary for MR1 signal transduction (34). Either bone marrow-derived antigen-presenting cell (APC) such as dendritic cells (27, 35), monocytes (9, 13), macrophages (35), B cells (36, 37), or non-bone marrow-derived epithelial cells (27, 37) can activate MAIT cells via MR1 (38).

As with conventional T cells, MR1-TCR signaling alone is insufficient to fully activate MAIT cells which also require co-stimulation (22, 38–40) by CD28 (39), TLR agonists, bacterial products or cytokines (22). Such cytokines include interleukin (IL)-7 (41, 42), tumor necrosis factor (TNF) (43), type-I interferons (IFNs) (44), IL-1β and/or IL-23 (38, 41). MAIT cells express several cytokine receptors including IL-7R, IL-12R, IL-15R, IL-18R, and IL-23R (9, 13, 38). IL-7 enhances MAIT cell responses to bacteria and promotes cytotoxicity (42). IL-12 and IL-18 potentiate MR1-dependent bacterial MAIT cell activation (34, 45). Agonists of the pathogen recognition receptors TLR1, TLR2 and TLR6 in humans (34), and TLR3, TLR4, TLR6/2, and TLR9 in mice (22, 46) promote MAIT cell activation mainly in an indirect way through the activation of APCs via enhancement of MR1 presentation, stimulation of cytotoxic molecules and inflammatory cytokines or up-regulation of co-stimulatory ligands (22, 34, 47, 48). In addition, inducible T cell co-stimulator (ICOS), highly expressed by MAIT cells is also essential for optimal activation and maintenance of retinoic acid-related orphan receptor γt (RORγt) expression (38).

Whilst the MAIT cell TCR-α chain is usually Vα7.2–Jα33/12/20 in humans, the β chain is more diverse: Vβ2 and Vβ13 are the most common. Some data suggest certain Vβ segments are associated with decreased TCR-dependent MAIT cell responses (49). Recently non-cognate TCR-dependent MAIT cell activation has been described for several bacterial superantigens. Although group A streptococci lack the riboflavin pathway, three molecules they produce bind specifically to Vβ2 leading to rapid TNF-dominated MAIT cell activation, likely contributing to the cytokine storm in streptococcal toxic shock syndrome (50). Likewise, in toxic shock induced by S. aureus, the staphylococcal enterotoxin B acts as a superantigen preferentially ligating MAIT cell Vβ13.2 with MHCII (51).

TCR-Independent Activation

In the absence of TCR-mediated antigen recognition, MAIT cells can also be partially activated by cytokines, such as IL-7, IL-12, IL-15, IL-18, and type-I IFNs, broadening the potential range of pathogens to which MAIT cells can respond to include viruses (35, 52–54). IL-7 can induce expression of cytolytic effector molecules (42). IL-12 or IL-15 together with IL-18, produced from APCs in response to TLR ligands, can directly stimulate MAIT cells to produce IFN-γ (35, 48, 55) and release granzyme B and perforin (45). IFN-α/β alone can activate MAIT cells but not induce cytokine production or upregulation of co-stimulatory molecules (44). Type-I IFNs induce significant IFN-γ and granzyme B only when combined with IL-12 or IL-18 (35). Likewise, the gut-associated pro-inflammatory cytokine, TNF-like protein 1A (TL1A/TNFSF15) activate MAIT cells in combination with IL-12 and IL-18 (56).

TCR-mediated and -independent activation work synergistically in optimal MAIT cell activation (Figure 1). Upon stimulation, there is increased expression of activation markers CD69 and CD25, degranulation marker CD107a (9, 25, 57), production of cytotoxic substances such as perforin and granzyme B (13, 42, 58), secretion of pro-inflammatory cytokines including IFN-γ, TNF, IL-17, and colony stimulating factor 2 (CSF2/GM-CSF) (9, 12, 13) and release of chemokines such as XCL1, CCL3, CCL4, and CXCL16 (40, 46). MAIT cells exert antimicrobial activity not only by direct recognition and killing of infected cells, but also indirectly, for example by recruiting neutrophils (59), increasing bactericidal activity of phagocytes (60), promoting the production of IFN-γ from DCs (35), and promoting monocyte to DC differentiation (61). Despite the considerable overlap in transcriptional and functional profiles, there are differences between these two modes of activation. TCR stimulation generally results in a more rapid immune response and multiple pro-inflammatory cytokines and chemokines production than cytokine stimulation alone. Elevated expression of RORγt, and the cytokines IL-17A, TNF, and CSF2 are seen with TCR-mediated activation, consistent with a Tc17-like phenotype (46, 59, 62), whilst TCR-independent activation is dominated by IFN-γ, perforin and granzyme B under the control of promyelocytic leukemia zinc finger (PLZF) (46) and T-bet (59), consistent with a Tc1-like phenotype. Importantly it is TCR-dependent activation which induces a tissue-repair programme (46, 56, 59). Knowing TCR-dependent and -independent MAIT cell responses are distinct, there remain many unanswered questions. For example, do MAIT cells shift between Tc17-like phenotype and Tc1-like phenotype? If such plasticity exists, what conditions are required and what are the influences?

FIGURE 1

Figure 1. MAIT cell activation. TCR-dependent activation requires microbially-derived riboflavin intermediates such as 5-OP-RU to be presented on MR1 to a MAIT cell TCR in conjunction with co-stimulation. Co-stimulation may include CD28 and/or cytokines particularly IL-12/-18, and can be induced by danger signals including TLR agonists (in mice TLRs 3, 4, 6/2, or 9, in human TLRs 1, 2, or 6). TCR dependent activation induces a strong and broad production of pro-inflammatory cytokines and chemokines, dominated by IL-17A under the control of the transcription factor RORγt. TCR-independent activation is driven by IL-18 in synergy with IL-12, or−15, or IFN-α or -β, and potentiated by TL1A. This activates a more modest cytokine response dominated by IFN-γ under the control of PLZF. APC, antigen-presenting cell; CD, cluster of differentiation; CSF2, colony stimulating factor 2 (GM-CSF); GzmB, granzyme B; IFN, interferon; IL, interleukin; MAIT, mucosal associated invariant T; MR1, major histocompatibility complex-related protein-1; PLZF, Promyelocytic leukaemia zinc finger protein; RORγt, retinoic acid-related orphan receptor gamma; TCR, T cell receptor; TL1A, tumor necrosis factor (TNF)-like protein 1A (TNFSF15); TLR, toll-like receptor.

MAIT Cell Functions in Infection

As a specific population of innate-like lymphoid cells, MAIT cells are involved in early immunity against infection in peripheral tissue, with a more rapid response to pathogens and shorter time to effector function in vivo than conventional MHC-restricted T cells in infectious disease (63). Next, we review MAIT cell functions antibacterial and antiviral host defense. The pathogens, activation elements, and effectors responses are summarized in Supplementary Table 1.

Antibacterial Host Defense

A wide range of bacterial, mycobacterial, and fungal pathogens have been shown to activate MAIT cells in vitro (Figure 2). These pathogens all express the riboflavin pathway and activation is via TCR-dependent activation. MAIT cells co-cultured with bacterially-infected monocytes (9, 13, 35, 51) or M. tuberculosis-infected lung epithelial cell lines (27) release IFN-γ in an MR-dependent manner. MAIT cell TCR-transgenic mice were better protected against infection by E. coli or M. abscessus than Mr1^−/− MAIT cell TCR-transgenic mice (9). Furthermore, bacterially-activated MAIT cells express perforin, undergo degranulation and can directly kill E. coli-infected human epithelial cell lines (HeLa-MR1) modified to over-express MR1 (25). With the intracellularly-invasive Shigella, this cell killing may occur in parental HeLa cells, suggesting a predilection for MAIT cells to respond to intracellular bacteria (25). Thus, there is potent inhibition of Mycobacterium bovis BCG growth within macrophages when co-cultured with MAIT cells (12). Consistent with this, Streptococcus pneumoniae has a poor capacity to activate MAIT cells when the APC is a monocyte or monocyte cell line, and this activation is dependent on cytokines rather than MR1 (64), perhaps because of monocytes' poor phagocytic and antigen-presenting capacity (65, 66). Conversely, S. pneumoniae does induce MR1-dependent activation in the presence of monocyte-derived macrophages, which have a greater phagocytic capacity (64). Likewise, S. pneumoniae activates MAIT cells in the presence of human monocyte-derived dendritic cells, in an MR1-dependent manner, with the extent of activation correlating with the activity of the RibD operon (24). In co-culture, MAIT cells reduce growth of S. pneumoniae within infected primary bronchial epithelial cells.

FIGURE 2

Figure 2. MAIT cell functions. Bacterially-infected cells present MAIT cell ligands on MR1 with co-stimulation and activate MAIT cell antibacterial defense functions including IFN-γ enhancement of antibacterial function in phagocytes, recruitment of neutrophils via IL-17 and differentiation of inflammatory monocytes to DCs in turn driving CD4 T cell recruitment. Virally infected cells produce IL-18, IL-12, IL-15, and type I interferons which upregulates IFN-γ with direct antiviral effects as well as direct cytotoxic MAIT cell functions via granzyme B, perforin, and Fas ligand. Commensal derived MAIT cell ligands, in the absence of co-stimulation stimulate MAIT cells to promote tissue homeostasis. Where a mucosal barrier is damaged these signals are enhanced and accompanied by damage signals to drive accelerated tissue repair signals. APC, antigen-presenting cell; CSF2, colony stimulating factor 2 (GM-CSF); DC, dendritic cell; FasL, Fas cell surface death receptor ligand; GzmB, granzyme B; IFN, interferon; IL, interleukin; MAIT, mucosal associated invariant T; MR1, major histocompatibility complex-related protein-1; TCR, T cell receptor.

To date, few pathogens have been found to induce MAIT cell expansion in vivo, and interestingly those that have are also predominantly intracellular pathogens. In a murine model, using a live vaccine strain (LVS) of the rare opportunistic intracellular pathogen Francisella tularensis, pulmonary MAIT cells expand markedly during acute intranasal infection (67). These cells express IFN-γ, IL-17, TNF, and inducible nitric oxide synthase (67) as well as GM-CSF which enhances pulmonary recruitment of inflammatory monocytes (61). There is impaired protection against infection by pulmonary F. tularensis LVS in CD4⁺CD8⁺-depleted MR1^−/− mice in contrast to their wild-type counterpart, which demonstrates MAIT cells' significance in mucosal immunity in absence of CD4⁺ and CD8⁺ T cells. In a second model of intracellular pulmonary bacterial infection, intranasal S. Typhimurium induced rapid, MR1-dependent expansion of pulmonary MAIT cells frequencies which persisted as an expanded population long-term comprising 35–50% of all pulmonary αβ T cells (22).

In the S. Typhimurium model, bacterial clearance was not dependent on MAIT cells, due to other redundant mechanisms including conventional CD4⁺ and CD8⁺ T cells (22). Impaired control of microbial growth in vivo has been observed with F. tularensis (61, 67) and the mycobacteria M. abscessus (9) and M. bovis BCG (12) in MR1^−/− mice which have an absolute deficiency of MAIT cells. In a murine model of Legionnaire's disease, two clinically-important strains of Legionella—pneumophila and longbeachae—activated human MAIT cells in vitro (62). L. longbeachae induced rapid pulmonary MAIT cell expansion, by up to 580-fold over 7 days, which persisted long-term, with a similar effect observed with L. pneumophila. 5-bromo-2′-deoxyuridine incorporation showed this was due to early, local MAIT cell proliferation in the lung and draining lymph node. MR1^−/− mice had delayed bacterial clearance at days 10–14 post-infection, although in both models this effect was small, due to immunological redundancy. To remove these additional layers of immunological redundancy, we adoptively transferred MR1-5-OP-RU positive MAIT cells into Rag2^−/−γC^−/− mice which lack T, B and NK cells. MAIT cells were sufficient to rescue mice completely from fatal L. longbeachae infection (62).

How do MAIT cells provide this protection? Using adoptive transfer from mice deficient in various signaling pathways, we showed this immune protection depended predominantly on MAIT cell IFN-γ, and to a lesser extent on GM-CSF, but not, with this organism, on perforin or granzyme (62). Legionella infects inflammatory cells, particularly neutrophils and macrophages, rather than epithelia and it is likely MAIT-derived IFN-γ limits intracellular growth of bacteria in these cells through multiple mechanisms including enhancement of oxidative burst, nitric oxide production, antigen presentation, phagocytosis and upregulation of CD80/86 co-stimulation, cytokines and chemokines (68). IFN-γ is also critical for protection against mycobacterial disease including M. tuberculosis, so this early production of MAIT cell-derived IFN-γ may likely be an important and non-redundant component of protection against mycobacteria. Indeed, polymorphism in MR1 is associated with susceptibility to M. tuberculosis (69).

Might MAIT cells be important in more common respiratory diseases? Persistent infection with Haemophilus influenzae, which can persist intracellularly (70), can drive inflammation in chronic obstructive pulmonary disease (COPD) (71) and severe neutrophilic asthma (72, 73) and enhance susceptibility to virally-induced inflammation (74, 75). MAIT cells are abundant in the normal airway mucosa, but we have shown frequencies are markedly reduced by therapeutic corticosteroids in both asthma (18) and COPD (19). In vitro H. influenzae enhances surface expression of MR1 on human pulmonary macrophages and induces MAIT cell IFN-γ, but both functions are also inhibited by corticosteroids, which may explain the enhanced susceptibility to bacterial pneumonias in airways diseases (19), suggesting a potential clinical benefit from more judicious use of inhaled steroids or MAIT-cell enhancing strategies.

MAIT cells are therefore capable of providing TCR-dependent rapid immune defense against a range of pathogenic intracellular bacteria. However, paradoxically, despite evidence of strong evolutionary pressure to maintain MAIT cell populations, it has been hard to identify a profound, non-redundant phenotype of pure MAIT cell deficiency either in the clinic or in animal models. The explanation may be that in addition to this undoubtedly important antibacterial role, it is now clear that MAIT cells perform additional roles in mucosal immunology, including antiviral host defense and tissue repair.

Antiviral Host Defense

Conventional T cells are critical for eventual clearance of most viruses by producing a peptide-specific cell-mediated immune response, which takes 4–7 days to evolve. Given their capacity for cytokine-mediated, TCR-independent activation, do MAIT cells play a role in anti-viral host-defense? Virus-induced activation of CD161⁺Vα7.2⁺ MAIT cells was observed in vivo in human peripheral blood MAIT cells during clinical infection of dengue, hepatitis C and influenza A (35), as well as at the peak viremia stage during acute infection by human immunodeficiency virus (76). Activation, measured by CD38 or granzyme B upregulation, increased during each infection in vivo whilst also in vitro MAIT cells upregulated CD69 and IFN-γ in the presence of virally-infected APCs. Similar findings were observed in a separate report of patients hospitalized with the H7N9 strain of influenza A virus, and interestingly higher MAIT cell frequencies were associated with subsequent recovery (53). Indeed cytokine-activated MAIT cells could reduce replication of hepatitis C in vitro in an IFN-γ dependent manner (35). However, the correlative clinical observations cannot prove causality, and neither study addressed whether the consequences of virus-induced MAIT cell activation in the intact host would be a beneficial contribution to antiviral defense, or conversely a worsening of immune-pathology, perhaps even augmentation of the cytokine-storm which can prove fatal in acute influenza infection.

To address this question we compared survival in mice infected with H1N1 influenza A virus in the presence or absence of an intact MR1: MAIT cell axis (52). MR1-tetramer⁺ MAIT cells accumulated in the lungs and were activated, with MAIT cell frequencies and CD25, CD69, and granzyme B upregulation peaking at day 5 post-infection, at least 48 h earlier than peak frequencies of conventional CD8⁺ T cells (defined as TCRβ⁺ CD45.2⁺ CD19⁻ MR1-5-OP-RU tetramer⁻ CD8⁺cells). Activation was dependent predominantly on IL-12 and to a lesser extent on IL-15, IL-18, and IFN-α. MAIT cell-deficient MR1^−/− mice showed enhanced weight loss and mortality which was ameliorated by prior adoptive transfer of pulmonary MAIT cells in both immunocompetent and immunodeficient Rag2^−/−γC^−/− mice. This confirmed that MAIT cells did not worsen immunopathology, but rather they contributed to immune protection. Moreover, current yearly influenza vaccines show limited efficacy and little heterologous protection between strains, whereas the TCR-independent nature of the antiviral MAIT cell response and the adoptive transfer experiments suggest the possibility of clinical benefit from therapeutic enhancement of airway MAIT cell numbers, such as a pre-exposure boosting using inhaled MAIT cell ligands. Such an approach would require clinical trials.

MAIT Cell Function in Tissue Repair and Homeostasis

Recently a third, distinct function has been discovered for MAIT cells. Using a transcriptomic approach on sorted MR1-tetramer⁺ cells, we sought to define the transcriptome of an activated MAIT cell in both human and mice. In addition to the strong expression of pro-inflammatory cytokines, we discovered in both species TCR-mediated activation-induced expression of a tissue-repair programme (46). The genes upregulated in both species included TNF, CSF2, HIF1A, FURIN, VEGFB, PTGES2, PDGFB, TGFB1, MMP25, and HMGB1. These genes had previously been identified as a geneset expressed by skin-homing Tc17 cells induced by commensal flora and able to accelerate repair of an epithelial wound in mice (77). Such Tc17 cells were restricted by another MHC class 1b molecule H2-M3, but this molecule is absent in humans and given their commensal dependence and capacity for IL-17 production it seemed likely MAIT cells might share this programme. Indeed in a comparative transcriptomic analysis of different T cell subsets in the ImmGen database (78) activated MAIT cells shared the greatest similarity with these commensal-induced epithelial Tc17 cells (46). This tissue repair programme is observed in MAIT cells stimulated by TCR ligands but not by cytokine-mediated stimulation alone (56, 59). Supernatants from TCR-activated MAIT cells accelerated wound closure in an intestinal epithelial cell line system (56).

Further studies in vivo have shown that skin colonization of germ-free mice with a common skin-commensal Staphylococcus epidermidis induced expansion of cutaneous MAIT cell populations and upregulation of this tissue repair programme in cutaneous MAIT cells (79). These MAIT cells are predominantly localized in the dermis near the dermal-epidermal junction and their MAIT cell expansion depended on 5-OP-RU and MR1. Moreover, these MAIT cells could accelerate the closure of a punch-biopsy induced skin wound, which was enhanced by application of topical 5-OP-RU.

Commensal organisms play a fundamental role in the development, function and homeostasis of the host immune system. Maintenance of the optimal symbiotic relationship between commensal microbiota and the immune system allows protective immune responses to occasional invasive pathogens (80, 81). Since MAIT cells are predominantly located in tissues colonized by commensal microbes, with broad antimicrobial specificity and tissue-repair function, MAIT cells' response to commensal organisms and tissue damage and infections may be as important for the restoration of homeostasis as their role in protection against pathogen invasion. Furthermore, it seems likely that, depending on the distinct tissue microenvironment, MAIT cells may express both antibacterial and also tissue repair functions at different stages in the evolution of an infectious or physical injury.

MAIT Cell Function in Autoimmunity and Inflammation

Conventional T cells are implicated as effectors in many organ-specific autoimmune diseases such as type-1 diabetes or multiple sclerosis, but strong HLA associations in a range of systemic autoimmune diseases imply a pathogenic role in these diseases as well. What role might MAIT cells play in these diseases? As the MAIT cell ligands are not synthesized by human cells, MAIT cell activation in these conditions would be presumed to be via the cytokine-mediated TCR-independent pathway. Changes in MAIT cell frequencies and phenotype are observed in a range of autoimmune conditions.

Blood MAIT cells are decreased in children with type 1 diabetes mellitus. In the non-obese diabetic mouse MR1^−/− mice have accelerated diabetes and increased gut permeability, suggesting MAIT cells may be protective against diabetes by supporting intestinal mucosal integrity, although the data are complicated by evidence in mice and humans of MAIT cell activation, exhaustion and capacity for islet-cell killing (82). Similarly, in type 2 diabetes peripheral blood MAIT cells are reduced in frequency, associated with increased caspase-3-dependent apoptosis (83).

In rheumatoid arthritis MAIT cell frequencies are increased in synovial tissue and so may contribute to maturation and cross-differentiation of T cells locally (84). Consistent with a pathogenic role, inflammation is reduced in murine collagen-induced arthritis in MR1^−/− mice (85).

MAIT cells are increased in inflammatory lesions in human multiple sclerosis (86), although data from animal models suggest they may play a protective role in the lesions as inflammation and pathology are reduced by adoptive transfer and exaggerated in MR1^−/− animals (87). Likewise, inflammation is suppressed by inhibitory MAIT cell ligands in an animal model of systemic lupus erythematosus (88).

In the gut, MAIT cells are found in proximity to Helicobacter pylori in human gastric mucosa, and in mice, MAIT cells were associated with accelerated H. pylori gastritis (89). In inflammatory bowel disease, several studies show decreases in peripheral blood MAIT cell frequencies and generally an increase in intestinal tissue (90–93), with increased IL-17 and IL-22 production by blood MAIT cells, although it remains to be seen if these changes are causally linked and whether they are pathogenic or protective by restoring mucosal integrity (94, 95).

Potential Clinical Translation of MAIT Cell Biology

Several characteristics of MAIT cells—their abundancy, their intrinsic effector memory phenotype (13), their mucosal distribution and the invariant nature of their receptor—make them excellent candidates to harness in the development of vaccines. In a therapeutic vaccine, for instance, for a respiratory infection, MAIT cell frequencies might be rapidly increased by stimulation with a MAIT cell ligand and co-stimulation, as has been shown in mice (22, 46, 62). More likely if more stable MAIT cell-activating ligands could be developed, these could be added to B cell or T cell prophylactic vaccines to enhance biological adjuvancy (96).

In autoimmune diseases in which MAIT cells had a predominantly pathological role, it would be possible to inhibit MAIT cells in a highly-selective manner using potent, inhibitory MAIT cell ligands such as acetyl-6-formylpterin (97). As orally-active small molecules, these could be attractive targets.

These cells' recently discovered role in promoting wound healing is perhaps the most exciting, from a translational perspective. Healing can be slow in chronic skin wounds such as leg ulcers, sacral pressure sores or burns, and could potentially be accelerated either by local wound re-colonization with riboflavin-synthesizing commensals, or through topical application of synthetic MAIT cell ligands. The latter approach has already been tested in a proof-of-principle murine study (79), and could very easily be translated into large-scale clinical trials.

In summary, the conservation and abundance of MAIT cells is likely explained by their broad range of functionality attributable to different modes of activation, each triggering a distinct transcriptomic programme. Because of their capability for diverse functional responses in diverse immunological contexts, these intriguing cells now appear to be multifunctional effectors central to the interface of innate and adaptive immunity. Already three major functions—antibacterial host defense, antiviral host defense, tissue repair and homeostasis—have been described for these intriguing cells, but it is likely other functions remain to be discovered.

Author Contributions

TH and X-WZ jointly conceived the article, conducted the literature review, and drafted the manuscript. All authors approved the final manuscript.

Funding

This work was supported by grants from the Wellcome Trust (104553/z/14/z, 211050/Z/18/z) and the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC) (to TH). The views expressed are those of the authors and not those of the NHS or NIHR.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The handling editor declared a past collaboration with one of the authors TH.

Supplementary Material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2020.01014/full#supplementary-material

Supplementary Table 1. Effects on MAIT cell activation and functions of various bacterial pathogens.

Abbreviations

5-OE-RU, 5-(2-oxoethylideneamino)-6-D-ribitylaminouracil; 5-OP-RU, 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil; MAIT, mucosal associated invariant T; MHC, major histocompatibility complex; MR1, major histocompatibility complex-related protein-1; TCR, T cell receptor.

References

1. Corbett AJ, Eckle SB, Birkinshaw RW, Liu L, Patel O, Mahony J, et al. T-cell activation by transitory neo-antigens derived from distinct microbial pathways. Nature. (2014) 509:361–5. doi: 10.1038/nature13160

PubMed Abstract | CrossRef Full Text | Google Scholar

2. Eckle SB, Corbett AJ, Keller AN, Chen Z, Godfrey DI, Liu L, et al. Recognition of vitamin b precursors and byproducts by mucosal associated invariant T cells. J Biol Chem. (2015) 290:30204–11. doi: 10.1074/jbc.R115.685990

PubMed Abstract | CrossRef Full Text | Google Scholar

3. Kjer-Nielsen L, Patel O, Corbett AJ, Le Nours J, Meehan B, Liu L, et al. MR1 presents microbial vitamin B metabolites to MAIT cells. Nature. (2012) 491:717–23. doi: 10.1038/nature11605

PubMed Abstract | CrossRef Full Text | Google Scholar

4. Treiner E, Duban L, Bahram S, Radosavljevic M, Wanner V, Tilloy F, et al. Selection of evolutionarily conserved mucosal-associated invariant T cells by MR1. Nature. (2003) 422:164–9. doi: 10.1038/nature01433

PubMed Abstract | CrossRef Full Text | Google Scholar

5. Tilloy F, Treiner E, Park SH, Garcia C, Lemonnier F, de la Salle H, et al. An invariant T cell receptor alpha chain defines a novel TAP-independent major histocompatibility complex class Ib-restricted alpha/beta T cell subpopulation in mammals. J Exp Med. (1999) 189:1907–21. doi: 10.1084/jem.189.12.1907

PubMed Abstract | CrossRef Full Text | Google Scholar

6. Reantragoon R, Corbett AJ, Sakala IG, Gherardin NA, Furness JB, Chen Z, et al. Antigen-loaded MR1 tetramers define T cell receptor heterogeneity in mucosal-associated invariant T cells. J Exp Med. (2013) 210:2305–20. doi: 10.1084/jem.20130958

PubMed Abstract | CrossRef Full Text | Google Scholar

7. Lepore M, Kalinicenko A, Colone A, Paleja B, Singhal A, Tschumi A, et al. Parallel T-cell cloning and deep sequencing of human MAIT cells reveal stable oligoclonal TCRbeta repertoire. Nat Commun. (2014) 5:3866. doi: 10.1038/ncomms5493

PubMed Abstract | CrossRef Full Text

8. Mak JY, Xu W, Reid RC, Corbett AJ, Meehan BS, Wang H, et al. Stabilizing short-lived Schiff base derivatives of 5-aminouracils that activate mucosal-associated invariant T cells. Nat Commun. (2017) 8:14599. doi: 10.1038/ncomms14599

PubMed Abstract | CrossRef Full Text | Google Scholar

9. Le Bourhis L, Martin E, Peguillet I, Guihot A, Froux N, Core M, et al. Antimicrobial activity of mucosal-associated invariant T cells. Nat Immunol. (2010) 11:701–8. doi: 10.1038/ni.1890

PubMed Abstract | CrossRef Full Text | Google Scholar

10. Maggio S, Takeda K, Stark F, Meierovics AI, Yabe I, Cowley SC. Control of Francisella tularensis intracellular growth by pulmonary epithelial cells. PLoS ONE. (2015) 10:e0138565. doi: 10.1371/journal.pone.0138565

PubMed Abstract | CrossRef Full Text | Google Scholar

11. Gold MC, Eid T, Smyk-Pearson S, Eberling Y, Swarbrick GM, Langley SM, et al. Human thymic MR1-restricted MAIT cells are innate pathogen-reactive effectors that adapt following thymic egress. Mucosal Immunol. (2013) 6:35–44. doi: 10.1038/mi.2012.45

PubMed Abstract | CrossRef Full Text | Google Scholar

12. Chua WJ, Truscott SM, Eickhoff CS, Blazevic A, Hoft DF, Hansen TH. Polyclonal mucosa-associated invariant T cells have unique innate functions in bacterial infection. Infect Immun. (2012) 80:3256–67. doi: 10.1128/IAI.00279-12

PubMed Abstract | CrossRef Full Text | Google Scholar

13. Dusseaux M, Martin E, Serriari N, Peguillet I, Premel V, Louis D, et al. Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17-secreting T cells. Blood. (2011) 117:1250–9. doi: 10.1182/blood-2010-08-303339

PubMed Abstract | CrossRef Full Text | Google Scholar

14. Seach N, Guerri L, Le Bourhis L, Mburu Y, Cui Y, Bessoles S, et al. Double-positive thymocytes select mucosal-associated invariant T cells. J Immunol. (2013) 191:6002–9. doi: 10.4049/jimmunol.1301212

PubMed Abstract | CrossRef Full Text | Google Scholar

15. Rahimpour A, Koay HF, Enders A, Clanchy R, Eckle SB, Meehan B, et al. Identification of phenotypically and functionally heterogeneous mouse mucosal-associated invariant T cells using MR1 tetramers. J Exp Med. (2015) 212:1095–108. doi: 10.1084/jem.20142110

PubMed Abstract | CrossRef Full Text | Google Scholar

16. Hinks T, Zhou X, Staples K, Dimitrov B, Manta A, Petrossian T, et al. Multidimensional endotypes of asthma: topological data analysis of cross-sectional clinical, pathological, and immunological data. Lancet. (2015) 385(Suppl. 1):S42. doi: 10.1016/S0140-6736(15)60357-9

PubMed Abstract | CrossRef Full Text | Google Scholar

17. Gherardin NA, Souter MN, Koay HF, Mangas KM, Seemann T, Stinear TP, et al. Human blood MAIT cell subsets defined using MR1 tetramers. Immunol Cell Biol. (2018) 96:507–25. doi: 10.1111/imcb.12021

PubMed Abstract | CrossRef Full Text | Google Scholar

18. Hinks TS, Zhou X, Staples KJ, Dimitrov BD, Manta A, Petrossian T, et al. Innate and adaptive T cells in asthmatic patients: relationship to severity and disease mechanisms. J Allergy Clin Immunol. (2015) 136:323–33. doi: 10.1016/j.jaci.2015.01.014

PubMed Abstract | CrossRef Full Text | Google Scholar

19. Hinks TS, Wallington JC, Williams AP, Djukanovic R, Staples KJ, Wilkinson TM. Steroid-induced deficiency of mucosal-associated invariant t cells in the COPD lung: implications for nthi infection. Am J Respir Crit Care Med. (2016) 194:1208–18. doi: 10.1164/rccm.201601-0002OC

PubMed Abstract | CrossRef Full Text | Google Scholar

20. Billerbeck E, Kang YH, Walker L, Lockstone H, Grafmueller S, Fleming V, et al. Analysis of CD161 expression on human CD8+ T cells defines a distinct functional subset with tissue-homing properties. Proc Natl Acad Sci USA. (2019) 107:3006–11. doi: 10.1073/pnas.0914839107

PubMed Abstract | CrossRef Full Text | Google Scholar

21. Huang S, Martin E, Kim S, Yu L, Soudais C, Fremont DH, et al. MR1 antigen presentation to mucosal-associated invariant T cells was highly conserved in evolution. Proc Natl Acad Sci USA. (2009) 106:8290–5. doi: 10.1073/pnas.0903196106

PubMed Abstract | CrossRef Full Text | Google Scholar

22. Chen Z, Wang H, D'Souza C, Sun S, Kostenko L, Eckle SB, et al. Mucosal-associated invariant T-cell activation and accumulation after in vivo infection depends on microbial riboflavin synthesis and co-stimulatory signals. Mucosal Immunol. (2017) 10:58–68. doi: 10.1038/mi.2016.39

PubMed Abstract | CrossRef Full Text | Google Scholar

23. Soudais C, Samassa F, Sarkis M, Le Bourhis L, Bessoles S, Blanot D, et al. In vitro and in vivo analysis of the gram-negative bacteria-derived riboflavin precursor derivatives activating mouse MAIT cells. J Immunol. (2015) 194:4641–9. doi: 10.4049/jimmunol.1403224

PubMed Abstract | CrossRef Full Text | Google Scholar

24. Hartmann N, McMurtrey C, Sorensen ML, Huber ME, Kurapova R, Coleman FT, et al. Riboflavin metabolism variation among clinical isolates of streptococcus pneumoniae results in differential activation of MAIT cells. Am J Respir Cell Mol Biol. (2018) 58:767–76. doi: 10.1165/rcmb.2017-0290OC

PubMed Abstract | CrossRef Full Text | Google Scholar

25. Le Bourhis L, Dusseaux M, Bohineust A, Bessoles S, Martin E, Premel V, et al. MAIT cells detect and efficiently lyse bacterially-infected epithelial cells. PLoS Pathog. (2013) 9:e1003681. doi: 10.1371/journal.ppat.1003681

PubMed Abstract | CrossRef Full Text | Google Scholar

26. Bernal I, Hofmann JD, Bulitta B, Klawonn F, Michel AM, Jahn D, et al. Clostridioides difficile activates human mucosal-associated invariant T cells. Front Microbiol. (2018) 9:2532. doi: 10.3389/fmicb.2018.02532

PubMed Abstract | CrossRef Full Text | Google Scholar

27. Gold MC, Cerri S, Smyk-Pearson S, Cansler ME, Vogt TM, Delepine J, et al. Human mucosal associated invariant T cells detect bacterially infected cells. PLoS Biol. (2010) 8:e1000407. doi: 10.1371/journal.pbio.1000407

PubMed Abstract | CrossRef Full Text | Google Scholar

28. Meermeier EW, Harriff MJ, Karamooz E, Lewinsohn DM. MAIT cells and microbial immunity. Immunol Cell Biol. (2018) 96:607–17. doi: 10.1111/imcb.12022

PubMed Abstract | CrossRef Full Text | Google Scholar

29. Jahreis S, Bottcher S, Hartung S, Rachow T, Rummler S, Dietl AM, et al. Human MAIT cells are rapidly activated by Aspergillus spp. in an APC-dependent manner. Eur J Immunol. (2018) 48:1698–706. doi: 10.1002/eji.201747312

PubMed Abstract | CrossRef Full Text | Google Scholar

30. Hashimoto K, Hirai M, Kurosawa Y. A gene outside the human MHC related to classical HLA class I genes. Science. (1995) 269:693–5. doi: 10.1126/science.7624800

PubMed Abstract | CrossRef Full Text | Google Scholar

31. Riegert P, Wanner V, Bahram S. Genomics, isoforms, expression, and phylogeny of the MHC class I-related MR1 gene. J Immunol. (1998) 161:4066–77.

PubMed Abstract | Google Scholar

32. McWilliam HE, Eckle SB, Theodossis A, Liu L, Chen Z, Wubben JM, et al. The intracellular pathway for the presentation of vitamin B-related antigens by the antigen-presenting molecule MR1. Nat Immunol. (2016) 17:531–7. doi: 10.1038/ni.3416

PubMed Abstract | CrossRef Full Text | Google Scholar

33. Harriff MJ, Karamooz E, Burr A, Grant WF, Canfield ET, Sorensen ML, et al. Endosomal MR1 trafficking plays a key role in presentation of Mycobacterium tuberculosis ligands to MAIT cells. PLoS Pathog. (2016) 12:e1005524. doi: 10.1371/journal.ppat.1005524

PubMed Abstract | CrossRef Full Text | Google Scholar

34. Ussher JE, van Wilgenburg B, Hannaway RF, Ruustal K, Phalora P, Kurioka A, et al. TLR signalling in human antigen-presenting cells regulates MR1-dependent activation of MAIT cells. Eur J Immunol. (2016) 46:1600–14. doi: 10.1002/eji.201545969

PubMed Abstract | CrossRef Full Text | Google Scholar

35. van Wilgenburg B, Scherwitzl I, Hutchinson EC, Leng T, Kurioka A, Kulicke C, et al. MAIT cells are activated during human viral infections. Nat Commun. (2016) 7:11653. doi: 10.1038/ncomms11653

PubMed Abstract | CrossRef Full Text

36. Salerno-Goncalves R, Rezwan T, Sztein MB. B cells modulate mucosal associated invariant T cell immune responses. Front Immunol. (2014) 4:511. doi: 10.3389/fimmu.2013.00511

PubMed Abstract | CrossRef Full Text | Google Scholar

37. Jeffery HC, van Wilgenburg B, Kurioka A, Parekh K, Stirling K, Roberts S, et al. Biliary epithelium and liver B cells exposed to bacteria activate intrahepatic MAIT cells through MR1. J Hepatol. (2016) 64:1118–27. doi: 10.1016/j.jhep.2015.12.017

PubMed Abstract | CrossRef Full Text | Google Scholar

38. Wang H, Kjer-Nielsen L, Shi M, D'Souza C, Pediongco TJ, Cao H, et al. IL-23 costimulates antigen-specific MAIT cell activation and enables vaccination against bacterial infection. Sci Immunol. (2019) 4:eaaw0402. doi: 10.1126/sciimmunol.aaw0402

PubMed Abstract | CrossRef Full Text | Google Scholar

39. Turtle CJ, Delrow J, Joslyn RC, Swanson HM, Basom R, Tabellini L, et al. Innate signals overcome acquired TCR signaling pathway regulation and govern the fate of human CD161(hi) CD8alpha(+) semi-invariant T cells. Blood. (2011) 118:2752–62. doi: 10.1182/blood-2011-02-334698

PubMed Abstract | CrossRef Full Text | Google Scholar

40. Slichter CK, McDavid A, Miller HW, Finak G, Seymour BJ, McNevin JP, et al. Distinct activation thresholds of human conventional and innate-like memory T cells. JCI Insight. (2016) 1:e86292. doi: 10.1172/jci.insight.86292

PubMed Abstract | CrossRef Full Text | Google Scholar

41. Tang XZ, Jo J, Tan AT, Sandalova E, Chia A, Tan KC, et al. IL-7 licenses activation of human liver intrasinusoidal mucosal-associated invariant T cells. J Immunol. (2013) 190:3142–52. doi: 10.4049/jimmunol.1203218

PubMed Abstract | CrossRef Full Text | Google Scholar

42. Leeansyah E, Svard J, Dias J, Buggert M, Nystrom J, Quigley MF, et al. Arming of MAIT cell cytolytic antimicrobial activity is induced by IL-7 and defective in HIV-1 infection. PLoS Pathog. (2015) 11:e1005072. doi: 10.1371/journal.ppat.1005072

PubMed Abstract | CrossRef Full Text | Google Scholar

43. Banki Z, Krabbendam L, Klaver D, Leng T, Kruis S, Mehta H, et al. Antibody opsonization enhances MAIT cell responsiveness to bacteria via a TNF-dependent mechanism. Immunol Cell Biol. (2019) 97:538–51. doi: 10.1111/imcb.12239

PubMed Abstract | CrossRef Full Text | Google Scholar

44. Lamichhane R, Galvin H, Hannaway RF, de la Harpe SM, Munro F, Tyndall JD, et al. Type I interferons are important co-stimulatory signals during T cell receptor mediated human MAIT cell activation. Eur J Immunol. (2020) 50:178–91. doi: 10.1002/eji.201948279

PubMed Abstract | CrossRef Full Text | Google Scholar

45. Sattler A, Dang-Heine C, Reinke P, Babel N. IL-15 dependent induction of IL-18 secretion as a feedback mechanism controlling human MAIT-cell effector functions. Eur J Immunol. (2015) 45:2286–98. doi: 10.1002/eji.201445313

PubMed Abstract | CrossRef Full Text | Google Scholar

46. T.Hinks SC, Marchi E, Jabeen M, Olshansky M, Kurioka A, Pediongco TJ, et al. Activation and in vivo evolution of the MAIT cell transcriptome in mice and humans reveals tissue repair functionality. Cell Rep. (2019) 28:3249–62 e5. doi: 10.1016/j.celrep.2019.07.039

PubMed Abstract | CrossRef Full Text | Google Scholar

47. Liu J, Brutkiewicz RR. The Toll-like receptor 9 signalling pathway regulates MR1-mediated bacterial antigen presentation in B cells. Immunology. (2017) 152:232–42. doi: 10.1111/imm.12759

PubMed Abstract | CrossRef Full Text | Google Scholar

48. Ussher JE, Bilton M, Attwod E, Shadwell J, Richardson R, de Lara C, et al. CD161++ CD8+ T cells, including the MAIT cell subset, are specifically activated by IL-12+IL-18 in a TCR-independent manner. Eur J Immunol. (2014) 44:195–203. doi: 10.1002/eji.201343509

PubMed Abstract | CrossRef Full Text | Google Scholar

49. Dias J, Leeansyah E, Sandberg JK. Multiple layers of heterogeneity and subset diversity in human MAIT cell responses to distinct microorganisms and to innate cytokines. Proc Natl Acad Sci USA. (2017) 114:E5434–43. doi: 10.1073/pnas.1705759114

PubMed Abstract | CrossRef Full Text | Google Scholar

50. Emgard J, Bergsten H, McCormick JK, Barrantes I, Skrede S, Sandberg JK, et al. MAIT cells are major contributors to the cytokine response in group a streptococcal toxic shock syndrome. Proc Natl Acad Sci USA. (2019) 116:25923–31. doi: 10.1073/pnas.1910883116

PubMed Abstract | CrossRef Full Text | Google Scholar

51. Shaler CR, Choi J, Rudak PT, Memarnejadian A, Szabo PA, Tun-Abraham ME, et al. MAIT cells launch a rapid, robust and distinct hyperinflammatory response to bacterial superantigens and quickly acquire an anergic phenotype that impedes their cognate antimicrobial function: defining a novel mechanism of superantigen-induced immunopathology and immunosuppression. PLoS Biol. (2017) 15:e2001930. doi: 10.1371/journal.pbio.2001930

PubMed Abstract | CrossRef Full Text | Google Scholar

52. Wilgenburg BV, Loh L, Chen Z, Pediongco TJ, Wang H, Shi M, et al. MAIT cells contribute to protection against lethal influenza infection in vivo. Nat Commun. (2018) 9:4706. doi: 10.1038/s41467-018-07207-9

PubMed Abstract | CrossRef Full Text

53. Loh L, Wang Z, Sant S, Koutsakos M, Jegaskanda S, Corbett AJ, et al. Human mucosal-associated invariant T cells contribute to antiviral influenza immunity via IL-18-dependent activation. Proc Natl Acad Sci USA. (2016) 113:10133–8. doi: 10.1073/pnas.1610750113

PubMed Abstract | CrossRef Full Text | Google Scholar

54. Ussher JE, Willberg CB, Klenerman P. MAIT cells and viruses. Immunol Cell Biol. (2018). doi: 10.1111/imcb.12008

CrossRef Full Text | Google Scholar

55. Jo J, Tan AT, Ussher JE, Sandalova E, Tang XZ, Tan-Garcia A, et al. Toll-like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver. PLoS Pathog. (2014) 10:e1004210. doi: 10.1371/journal.ppat.1004210

PubMed Abstract | CrossRef Full Text | Google Scholar

56. Leng T, Akther HD, Hackstein CP, Powell K, King T, Friedrich M, et al. TCR and inflammatory signals tune human MAIT cells to exert specific tissue repair and effector functions. Cell Rep. (2019) 28:3077–91 e5. doi: 10.1016/j.celrep.2019.08.050

PubMed Abstract | CrossRef Full Text | Google Scholar

57. Dias J, Sobkowiak MJ, Sandberg JK, Leeansyah E. Human MAIT-cell responses to Escherichia coli: activation, cytokine production, proliferation, and cytotoxicity. J Leukoc Biol. (2016) 100:233–40. doi: 10.1189/jlb.4TA0815-391RR

PubMed Abstract | CrossRef Full Text | Google Scholar

58. Kurioka A, Ussher JE, Cosgrove C, Clough C, Fergusson JR, Smith K, et al. MAIT cells are licensed through granzyme exchange to kill bacterially sensitized targets. Mucosal Immunol. (2014) 8:429–40. doi: 10.1038/mi.2014.81

PubMed Abstract | CrossRef Full Text | Google Scholar

59. Lamichhane R, Schneider M, de la Harpe SM, Harrop TWR, Hannaway RF, Dearden PK, et al. TCR- or cytokine-activated CD8(+) mucosal-associated invariant T cells are rapid polyfunctional effectors that can coordinate immune responses. Cell Rep. (2019) 28:3061–76 e5. doi: 10.1016/j.celrep.2019.08.054

PubMed Abstract | CrossRef Full Text | Google Scholar

60. Davey MS, Morgan MP, Liuzzi AR, Tyler CJ, Khan MW, Szakmany T, et al. Microbe-specific unconventional T cells induce human neutrophil differentiation into antigen cross-presenting cells. J Immunol. (2014) 193:3704–16. doi: 10.4049/jimmunol.1401018

PubMed Abstract | CrossRef Full Text | Google Scholar

61. Meierovics AI, Cowley SC. MAIT cells promote inflammatory monocyte differentiation into dendritic cells during pulmonary intracellular infection. J Exp Med. (2016) 213:2793–809. doi: 10.1084/jem.20160637

PubMed Abstract | CrossRef Full Text | Google Scholar

62. Wang H, D'Souza C, Lim XY, Kostenko L, Pediongco TJ, S.Eckle BG, et al. MAIT cells protect against pulmonary Legionella longbeachae infection. Nat Commun. (2018) 9:3350. doi: 10.1038/s41467-018-05202-8

PubMed Abstract | CrossRef Full Text | Google Scholar

63. Godfrey DI, Uldrich AP, McCluskey J, Rossjohn J, Moody DB. The burgeoning family of unconventional T cells. Nat Immunol. (2015) 16:1114–23. doi: 10.1038/ni.3298

PubMed Abstract | CrossRef Full Text | Google Scholar

64. Kurioka A, van Wilgenburg B, Javan RR, Hoyle R, van Tonder AJ, Harrold CL, et al. Diverse Streptococcus pneumoniae strains drive a mucosal-associated invariant T-cell response through major histocompatibility complex class i-related molecule-dependent and cytokine-driven pathways. J Infect Dis. (2018) 217:988–99. doi: 10.1093/infdis/jix647

PubMed Abstract | CrossRef Full Text | Google Scholar

65. Kamphorst AO, Guermonprez P, Dudziak D, Nussenzweig MC. Route of antigen uptake differentially impacts presentation by dendritic cells and activated monocytes. J Immunol. (2010) 185:3426–35. doi: 10.4049/jimmunol.1001205

PubMed Abstract | CrossRef Full Text | Google Scholar

66. Samstein M, Schreiber HA, Leiner IM, Susac B, Glickman MS, Pamer EG. Essential yet limited role for CCR2(+) inflammatory monocytes during Mycobacterium tuberculosis-specific T cell priming. Elife. (2013) 2:e01086. doi: 10.7554/eLife.01086

PubMed Abstract | CrossRef Full Text | Google Scholar

67. Meierovics A, Yankelevich WJ, Cowley SC. MAIT cells are critical for optimal mucosal immune responses during in vivo pulmonary bacterial infection. Proc Natl Acad Sci USA. (2013) 110:E3119–28. doi: 10.1073/pnas.1302799110

PubMed Abstract | CrossRef Full Text | Google Scholar

68. Ellis TN, Beaman BL. Interferon-gamma activation of polymorphonuclear neutrophil function. Immunology. (2004) 112:2–12. doi: 10.1111/j.1365-2567.2004.01849.x

PubMed Abstract | CrossRef Full Text | Google Scholar

69. Seshadri C, Thuong NT, Mai NT, Bang ND, Chau TT, Lewinsohn DM, et al. A polymorphism in human MR1 is associated with mRNA expression and susceptibility to tuberculosis. Genes Immun. (2017) 18:8–14. doi: 10.1038/gene.2016.41

PubMed Abstract | CrossRef Full Text | Google Scholar

70. Murphy TF, Kirkham C, Gallo MC, Yang Y, Wilding GE, Pettigrew MM. IgA protease variants facilitate intracellular survival in epithelial cells by nontypeable haemophilus influenzae that persist in the human respiratory tract in COPD. J Infect Dis. (2017) 216:1295–302. doi: 10.1093/infdis/jix471

PubMed Abstract | CrossRef Full Text | Google Scholar

71. Bafadhel M, Haldar K, Barker B, Patel H, Mistry V, Barer MR, et al. Airway bacteria measured by quantitative polymerase chain reaction and culture in patients with stable COPD: relationship with neutrophilic airway inflammation, exacerbation frequency, and lung function. Int J Chron Obstruct Pulmon Dis. (2015) 10:1075–83. doi: 10.2147/COPD.S80091

PubMed Abstract | CrossRef Full Text | Google Scholar

72. Simpson JL, Daly J, Baines KJ, Yang IA, Upham JW, Reynolds PN, et al. Airway dysbiosis: Haemophilus influenzae and Tropheryma in poorly controlled asthma. Eur Respir J. (2016) 47:792–800. doi: 10.1183/13993003.00405-2015

PubMed Abstract | CrossRef Full Text | Google Scholar

73. Singhania A, Wallington JC, Smith CG, Horowitz D, Staples KJ, Howarth PH, et al. Multitissue transcriptomics delineates the diversity of airway t cell functions in asthma. Am J Respir Cell Mol Biol. (2018) 58:261–70. doi: 10.1165/rcmb.2017-0162OC

PubMed Abstract | CrossRef Full Text | Google Scholar

74. Gulraiz F, Bellinghausen C, Bruggeman CA, Stassen FR. Haemophilus influenzae increases the susceptibility and inflammatory response of airway epithelial cells to viral infections. FASEB J. (2015) 29:849–58. doi: 10.1096/fj.14-254359

PubMed Abstract | CrossRef Full Text | Google Scholar

75. Bellinghausen C, Gulraiz F, Heinzmann AC, Dentener MA, Savelkoul PH, Wouters EF, et al. Exposure to common respiratory bacteria alters the airway epithelial response to subsequent viral infection. Respir Res. (2016) 17:68. doi: 10.1186/s12931-016-0382-z

PubMed Abstract | CrossRef Full Text | Google Scholar

76. Lal KG, Kim D, Costanzo MC, Creegan M, Leeansyah E, Dias J, et al. Dynamic MAIT cell response with progressively enhanced innateness during acute HIV-1 infection. Nat Commun. (2020) 11:272. doi: 10.1038/s41467-019-13975-9

PubMed Abstract | CrossRef Full Text | Google Scholar

77. Linehan JL, Harrison OJ, Han SJ, Byrd AL, Vujkovic-Cvijin I, Villarino AV, et al. Non-classical immunity controls microbiota impact on skin immunity and tissue repair. Cell. (2018) 172:784–96 e18. doi: 10.1016/j.cell.2017.12.033

PubMed Abstract | CrossRef Full Text | Google Scholar

78. Heng TS, Painter MW C. Immunological genome project, the immunological genome Project: networks of gene expression in immune cells. Nat Immunol. (2008) 9:1091–4. doi: 10.1038/ni1008-1091

PubMed Abstract | CrossRef Full Text | Google Scholar

79. Constantinides MG, Link VM, Tamoutounour S, Wong AC, Perez-Chaparro PJ, Han SJ, et al. MAIT cells are imprinted by the microbiota in early life and promote tissue repair. Science. (2019) 366:eaax6624. doi: 10.1126/science.aax6624

PubMed Abstract | CrossRef Full Text | Google Scholar

80. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell. (2014) 157:121–41. doi: 10.1016/j.cell.2014.03.011

PubMed Abstract | CrossRef Full Text | Google Scholar

81. Littman DR, Pamer EG. Role of the commensal microbiota in normal and pathogenic host immune responses. Cell Host Microbe. (2011) 10:311–23. doi: 10.1016/j.chom.2011.10.004

PubMed Abstract | CrossRef Full Text | Google Scholar

82. Rouxel O, Da Silva J, Beaudoin L, Nel I, Tard C, Cagninacci L, et al. Cytotoxic and regulatory roles of mucosal-associated invariant T cells in type 1 diabetes. Nat Immunol. (2017) 18:1321–31. doi: 10.1038/ni.3854

PubMed Abstract | CrossRef Full Text | Google Scholar

83. Zhang M, Ming S, Gong S, Liang S, Luo Y, Liang Z, et al. Activation-induced cell death of mucosal-associated invariant t cells is amplified by OX40 in type 2 diabetic patients. J Immunol. (2019) 203:2614–20. doi: 10.4049/jimmunol.1900367

PubMed Abstract | CrossRef Full Text | Google Scholar

84. Cho YN, Kee SJ, Kim TJ, Jin HM, Kim MJ, Jung HJ, et al. Mucosal-associated invariant T cell deficiency in systemic lupus erythematosus. J Immunol. (2014) 193:3891–901. doi: 10.4049/jimmunol.1302701

PubMed Abstract | CrossRef Full Text | Google Scholar

85. Chiba A, Tajima R, Tomi C, Miyazaki Y, Yamamura T, Miyake S. Mucosal-associated invariant T cells promote inflammation and exacerbate disease in murine models of arthritis. Arthritis Rheum. (2012) 64:153–61. doi: 10.1002/art.33314

PubMed Abstract | CrossRef Full Text | Google Scholar

86. Illes Z, Shimamura M, Newcombe J, Oka N, Yamamura T. Accumulation of Valpha7.2-Jalpha33 invariant T cells in human autoimmune inflammatory lesions in the nervous system. Int Immunol. (2004) 16:223–30. doi: 10.1093/intimm/dxh018

PubMed Abstract | CrossRef Full Text

87. Croxford JL, Miyake S, Huang YY, Shimamura M, Yamamura T. Invariant V(alpha)19i T cells regulate autoimmune inflammation. Nat Immunol. (2006) 7:987–94. doi: 10.1038/ni1370

PubMed Abstract | CrossRef Full Text | Google Scholar

88. Murayama G, Chiba A, Suzuki H, Nomura A, Mizuno T, Kuga T, et al. A critical role for mucosal-associated invariant t cells as regulators and therapeutic targets in systemic lupus erythematosus. Front Immunol. (2019) 10:2681. doi: 10.3389/fimmu.2019.02681

PubMed Abstract | CrossRef Full Text | Google Scholar

89. D'Souza C, Pediongco T, Wang H, Scheerlinck JY, Kostenko L, Esterbauer R, et al. Mucosal-associated invariant T cells augment immunopathology and gastritis in chronic Helicobacter pylori infection. J Immunol. (2018) 200:1901–16. doi: 10.4049/jimmunol.1701512

PubMed Abstract | CrossRef Full Text | Google Scholar

90. Serriari NE, Eoche M, Lamotte L, Lion J, Fumery M, Marcelo P, et al. Innate mucosal-associated invariant T (MAIT) cells are activated in inflammatory bowel diseases. Clin Exp Immunol. (2014) 176:266–74. doi: 10.1111/cei.12277

PubMed Abstract | CrossRef Full Text | Google Scholar

91. Hiejima E, Kawai T, Nakase H, Tsuruyama T, Morimoto T, Yasumi T, et al. Reduced numbers and proapoptotic features of mucosal-associated invariant t cells as a characteristic finding in patients with inflammatory bowel disease. Inflamm Bowel Dis. (2015) 21:1529–40. doi: 10.1097/MIB.0000000000000397

PubMed Abstract | CrossRef Full Text | Google Scholar

92. Haga K, Chiba A, Shibuya T, Osada T, Ishikawa D, Kodani T, et al. MAIT cells are activated and accumulated in the inflamed mucosa of ulcerative colitis. J Gastroenterol Hepatol. (2016) 31:965–72. doi: 10.1111/jgh.13242

PubMed Abstract | CrossRef Full Text | Google Scholar

93. Tominaga K, Yamagiwa S, Setsu T, Kimura N, Honda H, Kamimura H, et al. Possible involvement of mucosal-associated invariant T cells in the progression of inflammatory bowel diseases. Biomed Res. (2017) 38:111–21. doi: 10.2220/biomedres.38.111

PubMed Abstract | CrossRef Full Text | Google Scholar

94. Hinks TS. MAIT cells in autoimmunity, immune mediated diseases and airways disease. Immunology. (2016) 148:1–12. doi: 10.1111/imm.12582

PubMed Abstract | CrossRef Full Text | Google Scholar

95. Godfrey DI, Koay HF, McCluskey J, Gherardin NA. The biology and functional importance of MAIT cells. Nat Immunol. (2019) 20:1110–28. doi: 10.1038/s41590-019-0444-8

PubMed Abstract | CrossRef Full Text | Google Scholar

96. Downey AM, Kaplonek P, Seeberger PH. MAIT cells as attractive vaccine targets. FEBS Lett. (2019) 593:1627–40. doi: 10.1002/1873-3468.13488

PubMed Abstract | CrossRef Full Text | Google Scholar

97. Eckle SB, Birkinshaw RW, Kostenko L, Corbett AJ, McWilliam HE, Reantragoon R, et al. A molecular basis underpinning the T cell receptor heterogeneity of mucosal-associated invariant T cells. J Exp Med. (2014) 211:1585–600. doi: 10.1084/jem.20140484

PubMed Abstract | CrossRef Full Text | Google Scholar